ELUSYS THERAPEUTICS INC

Elusys Therapeutics Inc. specializes in the manufacturing of advanced biopharmaceutical countermeasures and the research and development of novel therapeutic agents, with a focused expertise in monoclonal antibody-based antitoxins for biothreat mitigation. The company has demonstrated technical proficiency in the end-to-end production of injectable biologics, including process development, formulation, and GMP-compliant manufacturing of anthrax antitoxins such as obiltoxaximab (ANTHIM). Their R&D capabilities encompass preclinical and clinical-stage biotechnology innovation, including protocol design, regulatory documentation, and lifecycle management of complex biologics under federal sponsorship. Key differentiators include deep experience in developing and scaling countermeasure products for public health emergencies, with a strong understanding of FDA regulatory pathways for biological products under the Animal Rule. The company maintains a sustained relationship with the Department of Health and Human Services, delivering both manufacturing and research support for biosecurity and medical countermeasure programs. Their work for HHS consistently aligns with the Biomedical Advanced Research and Development Authority’s mission, focusing on preparedness against chemical, biological, radiological, and nuclear threats. Elusys operates primarily within NAICS 325412 (pharmaceutical preparation manufacturing) and 541711 (biotechnology research and development), positioning itself as a niche provider of government-funded biologic countermeasures. Their market focus is on federally sponsored biosecurity initiatives, where they bridge the gap between early-stage discovery and scalable production of life-saving therapeutics. As a small business structured as a 2L entity based in Parsippany, New Jersey, Elusys Therapeutics Inc. is strategically located within a major biopharmaceutical corridor. While currently holding no formal government certifications, its track record in delivering high-compliance biologics for critical national health missions underscores its credibility and operational readiness within the federal biodefense ecosystem.